A Schlemm’s canal scaffold for the treatment of elevated IOP

Sruthi Sampathkumar, Andrew T. Schieber, Carol B. Toris

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Introduction: In the age of micro invasive /minimally invasive glaucoma surgery (MIGS), numerous glaucoma drainage devices are gaining importance. Hydrus is the latest device undergoing FDA approved clinical trials and is showing promising results in terms of intraocular pressure reduction in mild to moderate glaucoma when combined with cataract surgery. Areas covered: This review provides a detailed discussion of the preclinical and clinical trials of the Hydrus Microstent. A brief description of other new Schlemm’s canal based surgical procedures is also provided. An extensive literature search was made using the following keywords; Hydrus, Microstent, Schlemm’s canal scaffold, MIGS and outflow facility. Information on active clinical trials was obtained from clinicaltrails.gov. Recent and ongoing research activities on MIGS were obtained from abstracts presented at ARVO and AAO in recent years. Expert commentary: Hydrus microstent bypasses the trabecular meshwork and dilates a part of the Schlemm’s canal providing the aqueous humor with better access to collector channels and other downstream drainage vessels. Current and pending clinical trials will provide the long term safety and IOP efficacy of the Microstent. Only the future will determine whether MIGS will replace topical medications and lasers as a first line treatment option in glaucoma treatment.

Original languageEnglish (US)
Pages (from-to)259-266
Number of pages8
JournalExpert Review of Ophthalmology
Volume11
Issue number4
DOIs
StatePublished - Jul 3 2016

Fingerprint

Canals
Scaffolds
Glaucoma
Surgery
Minimally Invasive Surgical Procedures
Clinical Trials
Drainage
Therapeutics
Trabecular Meshwork
Equipment and Supplies
Aqueous Humor
Intraocular Pressure
Cataract
Lasers
Safety
Research

Keywords

  • Hydrus
  • MIGS
  • Microstent
  • Schlemm’s canal
  • glaucoma
  • outflow facility

ASJC Scopus subject areas

  • Biomedical Engineering
  • Ophthalmology
  • Optometry

Cite this

A Schlemm’s canal scaffold for the treatment of elevated IOP. / Sampathkumar, Sruthi; Schieber, Andrew T.; Toris, Carol B.

In: Expert Review of Ophthalmology, Vol. 11, No. 4, 03.07.2016, p. 259-266.

Research output: Contribution to journalReview article

Sampathkumar, Sruthi ; Schieber, Andrew T. ; Toris, Carol B. / A Schlemm’s canal scaffold for the treatment of elevated IOP. In: Expert Review of Ophthalmology. 2016 ; Vol. 11, No. 4. pp. 259-266.
@article{b6d2fb8997794ac1b1f75ceaa69d8a19,
title = "A Schlemm’s canal scaffold for the treatment of elevated IOP",
abstract = "Introduction: In the age of micro invasive /minimally invasive glaucoma surgery (MIGS), numerous glaucoma drainage devices are gaining importance. Hydrus is the latest device undergoing FDA approved clinical trials and is showing promising results in terms of intraocular pressure reduction in mild to moderate glaucoma when combined with cataract surgery. Areas covered: This review provides a detailed discussion of the preclinical and clinical trials of the Hydrus Microstent. A brief description of other new Schlemm’s canal based surgical procedures is also provided. An extensive literature search was made using the following keywords; Hydrus, Microstent, Schlemm’s canal scaffold, MIGS and outflow facility. Information on active clinical trials was obtained from clinicaltrails.gov. Recent and ongoing research activities on MIGS were obtained from abstracts presented at ARVO and AAO in recent years. Expert commentary: Hydrus microstent bypasses the trabecular meshwork and dilates a part of the Schlemm’s canal providing the aqueous humor with better access to collector channels and other downstream drainage vessels. Current and pending clinical trials will provide the long term safety and IOP efficacy of the Microstent. Only the future will determine whether MIGS will replace topical medications and lasers as a first line treatment option in glaucoma treatment.",
keywords = "Hydrus, MIGS, Microstent, Schlemm’s canal, glaucoma, outflow facility",
author = "Sruthi Sampathkumar and Schieber, {Andrew T.} and Toris, {Carol B.}",
year = "2016",
month = "7",
day = "3",
doi = "10.1080/17469899.2016.1210006",
language = "English (US)",
volume = "11",
pages = "259--266",
journal = "Expert Review of Ophthalmology",
issn = "1746-9899",
number = "4",

}

TY - JOUR

T1 - A Schlemm’s canal scaffold for the treatment of elevated IOP

AU - Sampathkumar, Sruthi

AU - Schieber, Andrew T.

AU - Toris, Carol B.

PY - 2016/7/3

Y1 - 2016/7/3

N2 - Introduction: In the age of micro invasive /minimally invasive glaucoma surgery (MIGS), numerous glaucoma drainage devices are gaining importance. Hydrus is the latest device undergoing FDA approved clinical trials and is showing promising results in terms of intraocular pressure reduction in mild to moderate glaucoma when combined with cataract surgery. Areas covered: This review provides a detailed discussion of the preclinical and clinical trials of the Hydrus Microstent. A brief description of other new Schlemm’s canal based surgical procedures is also provided. An extensive literature search was made using the following keywords; Hydrus, Microstent, Schlemm’s canal scaffold, MIGS and outflow facility. Information on active clinical trials was obtained from clinicaltrails.gov. Recent and ongoing research activities on MIGS were obtained from abstracts presented at ARVO and AAO in recent years. Expert commentary: Hydrus microstent bypasses the trabecular meshwork and dilates a part of the Schlemm’s canal providing the aqueous humor with better access to collector channels and other downstream drainage vessels. Current and pending clinical trials will provide the long term safety and IOP efficacy of the Microstent. Only the future will determine whether MIGS will replace topical medications and lasers as a first line treatment option in glaucoma treatment.

AB - Introduction: In the age of micro invasive /minimally invasive glaucoma surgery (MIGS), numerous glaucoma drainage devices are gaining importance. Hydrus is the latest device undergoing FDA approved clinical trials and is showing promising results in terms of intraocular pressure reduction in mild to moderate glaucoma when combined with cataract surgery. Areas covered: This review provides a detailed discussion of the preclinical and clinical trials of the Hydrus Microstent. A brief description of other new Schlemm’s canal based surgical procedures is also provided. An extensive literature search was made using the following keywords; Hydrus, Microstent, Schlemm’s canal scaffold, MIGS and outflow facility. Information on active clinical trials was obtained from clinicaltrails.gov. Recent and ongoing research activities on MIGS were obtained from abstracts presented at ARVO and AAO in recent years. Expert commentary: Hydrus microstent bypasses the trabecular meshwork and dilates a part of the Schlemm’s canal providing the aqueous humor with better access to collector channels and other downstream drainage vessels. Current and pending clinical trials will provide the long term safety and IOP efficacy of the Microstent. Only the future will determine whether MIGS will replace topical medications and lasers as a first line treatment option in glaucoma treatment.

KW - Hydrus

KW - MIGS

KW - Microstent

KW - Schlemm’s canal

KW - glaucoma

KW - outflow facility

UR - http://www.scopus.com/inward/record.url?scp=84980038910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980038910&partnerID=8YFLogxK

U2 - 10.1080/17469899.2016.1210006

DO - 10.1080/17469899.2016.1210006

M3 - Review article

AN - SCOPUS:84980038910

VL - 11

SP - 259

EP - 266

JO - Expert Review of Ophthalmology

JF - Expert Review of Ophthalmology

SN - 1746-9899

IS - 4

ER -